NCT06434909 - CYTALUX™for the Intraoperative Imaging of Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

July 24, 2025

Study Completion Date

July 24, 2025

Conditions

Prostate Cancer

Interventions

DRUG

Cytalux™ (pafolacianine) for fluorescent imaging

"Cytalux™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye for real-time cancer margin status.~This is used in conjunction with appropriate imaging system."

PROCEDURE

Image Guided Surgery

prostatectomy using appropriate imaging system

Trial Locations (3)

46032

IU Health Joe and Shelly Schwarz Cancer Center, Carmel

46202

Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

Indiana University Health Methodist Hospital, Indianapolis